We also demonstrated that this first-in-class covalent allosteric SHP1 inhibitor is efficacious as a monotherapy in a syngeneic MC38 mouse cancer model by triggering robust antitumor immunity, enhancing NK and CD8+ T cell function, and reducing T cell exhaustion. Here, CD8A is linked to cancer.